AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

METHOD TO PREDICT RESISTANCE OF CANCER CELLS TO ANTHRACYCLINE CHEMOTHERAPY

Technology Benefits

Breast, Prostate, Lung, Ovarian, Pancreatic, Liver, and Colon Cancers

Technology Application

The invention encompasses kits to detect presence and expression of LAPTM4B and/or YWHAZ genes and genetic products in tumor samples and describes method to use such kits as tools for selection of suitable treatments for cancer patients based on a prediction of likelihood of relapse, survival or outcome.

Detailed Technology Description

De novo resistance mechanisms present within tumor cells prior to treatment are key factors leading to failure of chemotherapeutic drugs to prevent metastatic recurrence. To identify the potential biomarkers of resistance, gene expression profiles of more than 100 breast carcinomas from women after anthracycline therapy were analyzed. It was discovered and proved by experimental approach that the amplification of the human 8q22-23 region in tumors and over-expression of genes residing in that chromosomal region, especially including the two genes, LAPTM4B and YWHAZ, is associated with and predictive of resistance to anthracycline-based chemotherapy. At the same time, the decreased resistance and enhanced chemotherapy efficacy were observed when expression of these genes was normal or low.

Country/Region

USA

For more information, please click Here